Optimizing Outcomes in Cold Agglutinin Disease: Exploring the Impact of Rapid Diagnosis and Emerging Therapeutic Agents

CME: 1.5

July 14, 2021
/ Print / Reprints /
| Share More
/ Text Size+

Target Audience

This educational activity is directed toward hematologists and hematologist-oncologists who treat patients with cold agglutinin disease. Fellows, nurses, nurse practitioners, and other health care professionals interested in the management of patients with cold agglutinin disease are also invited to participate.

Activity Overview

Cold agglutinin disease (CAD) has a significant impact on patients’ quality of life. Historically, the limited availability of treatment options has hindered management of CAD. However, the treatment landscape is shifting as novel therapies are developed based on improved understanding of the role of the complement system in the pathogenesis of CAD. Health care professionals require a strong foundation of knowledge in the efficacy, safety, and role of both available and emerging therapies for CAD to improve the outcomes in this patient population.

This program features experts presenting important topics on CAD, including the burden of disease and the impact of CAD on patient quality of life, as well as the role of the complement system in CAD. The program also includes expert review of current and emerging data surrounding strategies for rapid and accurate diagnosis, current management approaches and the potential of emerging treatments.

This educational activity is an archive of the live virtual presentation held on June 10, 2021.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the clinical burden of cold agglutinin disease.
  • Explain how the complement system is implicated in the onset of cold agglutinin disease.
  • Apply diagnostic criteria to facilitate an accurate and timely diagnosis of cold agglutinin disease.
  • Identify complement-mediated therapies for the treatment of cold agglutinin disease based on current and emerging evidence.

Post a comment to this article